Pharmaceuticals & Biotechnology
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Insider Trading: Significant insider selling noticed recently.
Profitability: Poor Profitability. Recent profit margins are negative at -29%.
Size: It is a very small market cap company. Risks of volatility, governance, sustained growth assumptions should be double checked.
Dividend: Stock hasn't been paying any dividend.
Momentum: Stock has a weak negative price momentum.
Past Returns: Underperforming stock! In past three years, the stock has provided -8.6% return compared to 12.2% by NIFTY 50.
Smart Money: Smart money is losing interest in the stock.
Balance Sheet: Company does NOT have a very strong balance sheet.
Technicals: SharesGuru indicator is Bearish.
Growth: Declining Revenues! Trailing 12m revenue has fallen by -48.5% in past one year. In past three years, revenues have changed by -68%.
Valuation | |
|---|---|
| Market Cap | 38.54 Cr |
| Price/Earnings (Trailing) | -2.31 |
| Price/Sales (Trailing) | 0.66 |
| EV/EBITDA | -7.91 |
| Price/Free Cashflow | 3.48 |
| MarketCap/EBT | -2.21 |
| Enterprise Value | 81.04 Cr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 58.48 Cr |
| Rev. Growth (Yr) | -9% |
| Earnings (TTM) | -16.7 Cr |
| Earnings Growth (Yr) | 121.9% |
Profitability | |
|---|---|
| Operating Margin | -30% |
| EBT Margin | -30% |
| Return on Equity | -117.41% |
| Return on Assets | -18.42% |
| Free Cashflow Yield | 28.71% |
Growth & Returns | |
|---|---|
| Price Change 1W | -2.6% |
| Price Change 1M | 0.10% |
| Price Change 6M | 44.1% |
| Price Change 1Y | -28.7% |
| 3Y Cumulative Return | -8.6% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -3.18 Cr |
| Cash Flow from Operations (TTM) | 11.49 Cr |
| Cash Flow from Financing (TTM) | -8.23 Cr |
| Cash & Equivalents | 28.17 L |
| Free Cash Flow (TTM) | 10.45 Cr |
| Free Cash Flow/Share (TTM) | 11.33 |
Balance Sheet | |
|---|---|
| Total Assets | 90.64 Cr |
| Total Liabilities | 76.42 Cr |
| Shareholder Equity | 14.22 Cr |
| Current Assets | 64.73 Cr |
| Current Liabilities | 67.9 Cr |
| Net PPE | 24.21 Cr |
| Inventory | 56.68 Cr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.47 |
| Debt/Equity | 3.01 |
| Interest Coverage | -4.75 |
| Interest/Cashflow Ops | 4.33 |
Dividend & Shareholder Returns | |
|---|---|
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Summary of Vineet Lab's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Last updated:
Last updated:
Understand Vineet Lab ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| GADDAM VENKATA RAMANA | 6.32% |
| RAJESH PODDAR | 4.48% |
| SUREKHA NAGA LAKSHMI PENDELA | 4.37% |
| SATYANARAYANA RAJU BHUPATHIRAJU | 1.92% |
| RAJENDRA AGRAWAL | 1.57% |
| AJAY AGRAWAL | 1.53% |
| ARJUN AGGARWAL | 1.52% |
| ANASUYA GORLA | 1.47% |
| JYOTI AGARWAL | 1.39% |
| A RANGA RAJU | 1.31% |
| A PRABHAKAR RAJU | 1.25% |
| A SRINIVASA RAJU | 1.18% |
| ALLURI MYTHILI | 1.14% |
| SEETARAMANJANEYULU N | 1.07% |
| VIROCHAN MEHTA | 1.03% |
| ALLURI ANANTHA LAXMI | 0.82% |
| PENMETSA VENKATA KRISHNAM RAJU | 0.69% |
| P KISHORE RAJU | 0.57% |
| GADDAM SRINIVASARAO | 0.39% |
| GADDAM VENKATA RAMA | 0.27% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Vineet Lab against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Comprehensive comparison against sector averages
VINEETLAB metrics compared to Pharmaceuticals
| Category | VINEETLAB | Pharmaceuticals |
|---|---|---|
| PE | -2.31 | 35.17 |
| PS | 0.66 | 4.95 |
| Growth | -48.5 % | 10.3 % |
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and fine chemicals in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was founded in 2007 and is based in Hyderabad, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
VINEETLAB vs Pharmaceuticals (2022 - 2025)